Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock

Pietro Caironi, Roberto Latini, Joachim Struck, Oliver Hartmann, Andreas Bergmann, Valentina Bellato, Sandra Ferraris, Gianni Tognoni, Antonio Pesenti, Luciano Gattinoni, Serge Masson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: Acute kidney injury (AKI) occurs in many critically ill patients and is associated with high mortality. We examined whether proenkephalin could predict incident AKI and its improvement in septic patients. METHODS: Plasma proenkephalin A 119-159 (penKid) was assayed in 956 patients with sepsis or septic shock enrolled in the multicenter Albumin Italian Outcome Sepsis (ALBIOS) trial to test its association with incident AKI, improvement of renal function, need for renal replacement therapy (RRT), and mortality. RESULTS: Median [Q1-Q3] plasma penKid concentration on day 1 [84 (20 -159) pmol/L[ was correlated with serum creatinine concentration (r= 0.74); it was higher in patients with chronic renal failure and rose progressively with the renal Sequential Organ Failure Assessment subscore. It predicted incident AKI within 48 h (adjusted odds ratio, 3.3; 95% CI, 2.1-5.1; P< 0.0001) or 1 week [adjusted hazard ratio, 2.1 (1.7-2.8); P< 0.0001] and future RRT during the intensive care unit stay [odds ratio, 4.0 (3.0 -5.4)]. PenKid was also associated with improvements in renal function in patients with baseline serum creatinine >2 mg/dL, both within the next 48 h [adjusted odds ratio, 0.31 (0.18-0.54), P< 0.0001] and 1 week [0.23 (0.12- 0.45)]. The time course of penKid concentrations predicted AKI and 90-day mortality. CONCLUSIONS: Early measurement and the trajectory of penKid predict incident AKI, improvement of renal function, and the need for RRT in the acute phase after intensive care unit admission during sepsis or septic shock. PenKid measurement may be a valuable tool to test early therapies aimed at preventing the risk of AKI in sepsis.

Original languageEnglish
Pages (from-to)1361-1369
Number of pages9
JournalClinical Chemistry
Volume64
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Acute Kidney Injury
Shock
Sepsis
Plasmas
Intensive care units
Albumins
Creatinine
Trajectories
Renal Replacement Therapy
Septic Shock
Kidney
Mortality
Odds Ratio
Secondary Prevention
proenkephalin
Critical Illness
Chronic Kidney Failure
Intensive Care Units
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock. / Caironi, Pietro; Latini, Roberto; Struck, Joachim; Hartmann, Oliver; Bergmann, Andreas; Bellato, Valentina; Ferraris, Sandra; Tognoni, Gianni; Pesenti, Antonio; Gattinoni, Luciano; Masson, Serge.

In: Clinical Chemistry, Vol. 64, No. 9, 01.09.2018, p. 1361-1369.

Research output: Contribution to journalArticle

Caironi, P, Latini, R, Struck, J, Hartmann, O, Bergmann, A, Bellato, V, Ferraris, S, Tognoni, G, Pesenti, A, Gattinoni, L & Masson, S 2018, 'Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock', Clinical Chemistry, vol. 64, no. 9, pp. 1361-1369. https://doi.org/10.1373/clinchem.2018.288068
Caironi, Pietro ; Latini, Roberto ; Struck, Joachim ; Hartmann, Oliver ; Bergmann, Andreas ; Bellato, Valentina ; Ferraris, Sandra ; Tognoni, Gianni ; Pesenti, Antonio ; Gattinoni, Luciano ; Masson, Serge. / Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock. In: Clinical Chemistry. 2018 ; Vol. 64, No. 9. pp. 1361-1369.
@article{ecbb9a7c390349bbba65133766ed8dc0,
title = "Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock",
abstract = "BACKGROUND: Acute kidney injury (AKI) occurs in many critically ill patients and is associated with high mortality. We examined whether proenkephalin could predict incident AKI and its improvement in septic patients. METHODS: Plasma proenkephalin A 119-159 (penKid) was assayed in 956 patients with sepsis or septic shock enrolled in the multicenter Albumin Italian Outcome Sepsis (ALBIOS) trial to test its association with incident AKI, improvement of renal function, need for renal replacement therapy (RRT), and mortality. RESULTS: Median [Q1-Q3] plasma penKid concentration on day 1 [84 (20 -159) pmol/L[ was correlated with serum creatinine concentration (r= 0.74); it was higher in patients with chronic renal failure and rose progressively with the renal Sequential Organ Failure Assessment subscore. It predicted incident AKI within 48 h (adjusted odds ratio, 3.3; 95{\%} CI, 2.1-5.1; P< 0.0001) or 1 week [adjusted hazard ratio, 2.1 (1.7-2.8); P< 0.0001] and future RRT during the intensive care unit stay [odds ratio, 4.0 (3.0 -5.4)]. PenKid was also associated with improvements in renal function in patients with baseline serum creatinine >2 mg/dL, both within the next 48 h [adjusted odds ratio, 0.31 (0.18-0.54), P< 0.0001] and 1 week [0.23 (0.12- 0.45)]. The time course of penKid concentrations predicted AKI and 90-day mortality. CONCLUSIONS: Early measurement and the trajectory of penKid predict incident AKI, improvement of renal function, and the need for RRT in the acute phase after intensive care unit admission during sepsis or septic shock. PenKid measurement may be a valuable tool to test early therapies aimed at preventing the risk of AKI in sepsis.",
author = "Pietro Caironi and Roberto Latini and Joachim Struck and Oliver Hartmann and Andreas Bergmann and Valentina Bellato and Sandra Ferraris and Gianni Tognoni and Antonio Pesenti and Luciano Gattinoni and Serge Masson",
year = "2018",
month = "9",
day = "1",
doi = "10.1373/clinchem.2018.288068",
language = "English",
volume = "64",
pages = "1361--1369",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "9",

}

TY - JOUR

T1 - Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock

AU - Caironi, Pietro

AU - Latini, Roberto

AU - Struck, Joachim

AU - Hartmann, Oliver

AU - Bergmann, Andreas

AU - Bellato, Valentina

AU - Ferraris, Sandra

AU - Tognoni, Gianni

AU - Pesenti, Antonio

AU - Gattinoni, Luciano

AU - Masson, Serge

PY - 2018/9/1

Y1 - 2018/9/1

N2 - BACKGROUND: Acute kidney injury (AKI) occurs in many critically ill patients and is associated with high mortality. We examined whether proenkephalin could predict incident AKI and its improvement in septic patients. METHODS: Plasma proenkephalin A 119-159 (penKid) was assayed in 956 patients with sepsis or septic shock enrolled in the multicenter Albumin Italian Outcome Sepsis (ALBIOS) trial to test its association with incident AKI, improvement of renal function, need for renal replacement therapy (RRT), and mortality. RESULTS: Median [Q1-Q3] plasma penKid concentration on day 1 [84 (20 -159) pmol/L[ was correlated with serum creatinine concentration (r= 0.74); it was higher in patients with chronic renal failure and rose progressively with the renal Sequential Organ Failure Assessment subscore. It predicted incident AKI within 48 h (adjusted odds ratio, 3.3; 95% CI, 2.1-5.1; P< 0.0001) or 1 week [adjusted hazard ratio, 2.1 (1.7-2.8); P< 0.0001] and future RRT during the intensive care unit stay [odds ratio, 4.0 (3.0 -5.4)]. PenKid was also associated with improvements in renal function in patients with baseline serum creatinine >2 mg/dL, both within the next 48 h [adjusted odds ratio, 0.31 (0.18-0.54), P< 0.0001] and 1 week [0.23 (0.12- 0.45)]. The time course of penKid concentrations predicted AKI and 90-day mortality. CONCLUSIONS: Early measurement and the trajectory of penKid predict incident AKI, improvement of renal function, and the need for RRT in the acute phase after intensive care unit admission during sepsis or septic shock. PenKid measurement may be a valuable tool to test early therapies aimed at preventing the risk of AKI in sepsis.

AB - BACKGROUND: Acute kidney injury (AKI) occurs in many critically ill patients and is associated with high mortality. We examined whether proenkephalin could predict incident AKI and its improvement in septic patients. METHODS: Plasma proenkephalin A 119-159 (penKid) was assayed in 956 patients with sepsis or septic shock enrolled in the multicenter Albumin Italian Outcome Sepsis (ALBIOS) trial to test its association with incident AKI, improvement of renal function, need for renal replacement therapy (RRT), and mortality. RESULTS: Median [Q1-Q3] plasma penKid concentration on day 1 [84 (20 -159) pmol/L[ was correlated with serum creatinine concentration (r= 0.74); it was higher in patients with chronic renal failure and rose progressively with the renal Sequential Organ Failure Assessment subscore. It predicted incident AKI within 48 h (adjusted odds ratio, 3.3; 95% CI, 2.1-5.1; P< 0.0001) or 1 week [adjusted hazard ratio, 2.1 (1.7-2.8); P< 0.0001] and future RRT during the intensive care unit stay [odds ratio, 4.0 (3.0 -5.4)]. PenKid was also associated with improvements in renal function in patients with baseline serum creatinine >2 mg/dL, both within the next 48 h [adjusted odds ratio, 0.31 (0.18-0.54), P< 0.0001] and 1 week [0.23 (0.12- 0.45)]. The time course of penKid concentrations predicted AKI and 90-day mortality. CONCLUSIONS: Early measurement and the trajectory of penKid predict incident AKI, improvement of renal function, and the need for RRT in the acute phase after intensive care unit admission during sepsis or septic shock. PenKid measurement may be a valuable tool to test early therapies aimed at preventing the risk of AKI in sepsis.

UR - http://www.scopus.com/inward/record.url?scp=85052471054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052471054&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2018.288068

DO - 10.1373/clinchem.2018.288068

M3 - Article

AN - SCOPUS:85052471054

VL - 64

SP - 1361

EP - 1369

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 9

ER -